R. Rodriguez-Roisin (Barcelona, Spain), B. R. Celli (Wellesley, United States of America)
Elevated C-reactive protein is associated with reduced lung function and exercise capacity in normal subjects. Are we born inflammed?
V. M. Pinto-Plata, H. Mullerova, B. R. Celli (Boston, United States Of America; London, United Kingdom)
|  |
Tolerability and pharmacokinetics of inhaled bimosiamose in healthy human volunteers
M. Meyer, K. M. Beeh, J. Beier, E. Aydt, R. Zahlten, B. Jilma, G. Wolff (Berlin, Wiesbaden, Germany; Vienna, Austria)
| |
Prognostic value of C-reactive protein in patients with severe to very severe chronic obstructive pulmonary disease
E. Balestro, F. Dal Farra, U. Pastore, G. Da Rin, G. Rossi, S. Calabro (Bassano del Grappa, Italy)
|  |
Hyperglycaemia and its association with outcomes in people admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease
S. Tryfon, M. Saroglou, A. Kosma, V. Dramba, N. Galanis (Exohi- Thessaloniki, Greece)
| |
Systemic inflammation and increased arterial stiffness in patients with chronic obstructive pulmonary disease
J. J. Miller, A. Anand, S. D. Robinson, I. B. Wilkinson, C. M. McEniery, G. A. Frazer, I. B. Wilkinson, K. Donaldson, D. E. Newby, W. MacNee, N. L. Mills (Edinburgh, Cambridge, United Kingdom)
| |
Reliability of cause-specific mortality adjudication in the TORCH clinical trial
L. P. A. McGarvey, M. John, J. A. Anderson, M. T. Zvarich, R. A. Wise (Belfast, Greenford, United Kingdom; Prerow, Germany; RTP, Baltimore, United States Of America)
| |
Periodontitis and chronic obstructive pulmonary disease
I. Leuckfeld, M. V. Obregon-Whittle, I. Olsen, O. Geiran, O. Bjortuft (Oslo, Norway)
| |
Role of antibiotics in exacerbations of chronic obstructive pulmonary disease: a Cochrane review
F. S. F. Ram, R. Rodriguez-Roisin, A. Granados-Navarrete, J. Garcia-Aymerich, N. C. Barnes (Auckland, New Zealand; Barcelona, Spain; London, United Kingdom)
| |